Donghai Securities: Operating conditions in the pharmaceutical sector continue to stabilize, with the innovative drug pipeline remaining the core investment focus.

Overall, the pharmaceutical and biotechnology sector offers significant medium- to long-term investment value, and we recommend actively positioning in high-quality stocks within relevant sub-sectors.

Zhitong FinanceJul 10 11:40

Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech

WSJJul 7 05:53

Industrial Securities: Continued share buybacks demonstrate corporate confidence; remain bullish on innovative drugs and the innovative drug supply chain.

Chinese CDMOs have become core global suppliers of novel molecules, leveraging capacity expansion, project experience, and global footprint.

Zhitong FinanceJul 3 13:45

Tech-Bio Co., Ltd. (688278.SH): Repurchased 1.79% of the company's shares cumulatively

Gelonghui, July 1 — Tech-Bio Co., Ltd. (SHA: 688278) announced that, as of June 30, 2026, the company had cumulatively repurchased 7,313,400 of its own shares through the centralized bidding trading system of the Shanghai Stock Exchange, representing 1.79% of the company's total share capital. The highest repurchase price was RMB 57.20 per share, and the lowest was RMB 52.62 per share, with a total amount of RMB 403 million paid (excluding stamp duty, trading commissions, and other transaction fees).

Gelonghui FinanceJul 1 17:37

Terumo Biopharma (688278.SH) received CSRC approval for the registration of its convertible bond issuance.

Tech-Bio Co., Ltd. (SHA: 688278) announced that the company recently received the "Approval on the Registration of Convertible Bonds Issued to Unspecified Objects by Xiamen Tech-Bio Bioengineering Co., Ltd." issued by the China Securities Regulatory Commission (CSRC), approving the company's registration application for issuing convertible bonds to unspecified objects.

Zhitong FinanceJun 25 17:54

Terapai Bio (688278.SH): Has cumulatively repurchased 2.24% of the company's shares.

Gelonghui, June 18 — Tech-Bio Co., Ltd. (SHA: 688278) announced that the company is implementing its second share repurchase plan for 2026. As of June 17, 2026, a total of 5.7014 million shares had been repurchased under this second repurchase plan, with the highest transaction price at RMB 57.20 per share and the lowest at RMB 53.44 per share, amounting to a total payment of RMB 316 million (excluding stamp duty, brokerage commissions, and other transaction fees). As of June 17, 2026, the company’s first and second share repurchase plans for 2026 have been executed through the Shanghai Stock Exchange.

Gelonghui FinanceJun 18 01:08